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T he history of whole-organ grafting th rough 1959 
was largely confined to the kidney.! The vacuum 
began to fill during the mid and late 1950s with the 
development in several laboratories of canine trans-
plant models with which to study all of the intra-ab-
dominal and thoracic organs. Although it was not ap-
preciated at the outset, the intimate anatomic, 
metabolic, and immunologic relationships of each of 
the intra-abdominal viscera (Figure 1) eventually in-
fluenced the conditions for transplantation of all of 
the others. 
The Liver 
In this revolution, the liver occupied a unique 
position, not only because it was the first vital organ 
beyond the kidney to be engrafted successfully in hu-
mans, but also because of the secrets yielded by re-
search on its transplantation. Hepatic transplantation 
was introduced to the scientific literature in 1955 by C. 
Stuart Welch of Albany, New York, who described in 
dogs the insertion of an extra (auxiliary) liver into the 
pel v is or right paravertebral gutter of the recipient. 2 
The allograft hepatic artery was revascularized from 
the aorta or iliac artery, and the portal flow was re-
stored by rerouting the high-volume systemic venous 
return of the host inferior vena cava into the graft 
portal vein. 
When the livers were destroyed within a few days in 
the non immunosuppressed animals, it was concluded 
that rejection was solely responsible. This was an un-
derstandable interpretation. After nearly 80 years of 
research on the experimental procedure of Eck's fis-
tula (portacaval shunt), the dogma of 1955 was that 
the high concentration of hormones and nutrients in 
splanchnic venous blood had no relevance to liver 
structure or function or the capacity for regeneration. 3 
The presumed nonspecificity of splanchnic venous 
blood was the central strut of the seemingly impregna-
ble flow hypothesis of portal physiology which held 
that "all blood is equal." 
In spite of his mistake in attributing auxiliary graft 
destruction to rejection alone, what \'\;'elch had done 
unwittingly was to create an experimental model of 
great power. The principle of the model was the coex-
istence of two livers in the same animal with identical 
conditions except for the constituency of the blood 
delivered to the graft and native portal veins. When 
Welch's experiments were repeated in 1963 under im-
munosuppression, auxiliary livers protected from re-
jection by azathioprine but deprived of splanchnic ve-
nous inflow shrank within a few days to a fraction of 
their original size. 4 
It soon became apparent that the liver with first 
access to the portal blood was able to remove sub-
stance(s) so completely that little was left for the com-
peting organ. Insulin was the most easily identified of 
the portal blood factors, but it has long been known 
that the so-called hepatotrophic substances are multi-
ple. 5 As new growth factors of pancreatic and enteric 
origin have become available in recent years, they have 
been discovered or screened with non transplant mod-
els that in one way or other are direct descendents of 
the original auxiliary allograft (double-liver) prepara-
tions. 6 
The liver-replacement operation (orthotopic trans-
plantation) in common clinical use today was first re-
ported by Jack Cannon of the University of California, 
Los Angeles, who cited Welch's article as the stimulus 
for his own "several successful" replacement opera-
tions in dogs "without survival of the patient."7 With 
the assumption that the liver played an important role 
in rejection, Cannon speculated that the graft would 
not contribute to its own repudiation. Details of his 
new operation were not given, and the procedure re-
mained virtually unknown until major programs of 
canine "orthotopic" liver transplantation were begun 
at the Peter Bent Brigham Hospital (Harvard)8 and 
independently at Northwestern University in Chi-
cago.9 At the time, there was no effective way to pre-
vent rejection, nor would this objective be achievable 
for several more years. 
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Figure 1. The complex of intra·abdominal viscera (center) from which come liver-pancreas, intestine, pancreas, or liver grafts (periphery). 
The Boston effort under the direction of Francis D. 
Moore was part of an immunologically oriented insti-
tutional commitment to organ transplantation that ex-
tended back more than a decade previously with an 
initial emphasis on the kidney.1O The Northwestern 
initiative stemmed from a hypothesis that the liver was 
a modulator of insulin activity or in turn was governed 
by this hormone. 11 In the course of the metabolic in-
vestigations, a new technique of total hepatectomy 
(the first half of a transplant operation),12 and ulti-
mately the insertion of an allograft into the vacated 
hepatic fossa,9 were viewed at first as tools for meta-
bolic investigations. 
The superior liver-supporting qualities of portal ve-
nous blood were easily demonstrable by the results of 
the transplant experiments.9 The other requirements 
for successful liver replacement also were straightfor-
ward. Intraportal infusion of the transplanted liver 
with chilled solutions during its removal allowed ef-
fective short-term storage in much the same way as in 
clinical operating rooms today.9lmproved infusates in 
the succeeding years 13,14 eventually replaced the origi-
nally used lactated Ringer's and saline solutions. Since 
1987, the University of Wisconsin solution developed 
by Belzer and Southard15 has permitted the safe refrig-
eration of human livers for 18-24 hours. 
Orthotopic liver transplantation could not be ac-
complished consistently in dogs without plastic exter-
nal venous bypasses that passively redirected blood 
from the occluded splanchnic and systemic venous 
pools to the superior vena cava during the so-called 
an hepatic stage while recipient hepatectomy was per-
formed and the new liver was sewn in. 8,9 Such venous 
decompression was later shown to be expendable in 
most clinical cases by experienced surgeons. 16 How-
ever, the introduction in 1983 of pump-driven by-
passes without anticoagulation made the operation less 
stressful and placed it well within the grasp of most 
competent general and vascular surgeons. 17 
The sense of futility in the late 1950s at developing 
an operation that had no conceivable clinical use 
changed abruptly with the discovery by Schwartz and 
Dameshek of the immunosuppressive qualities of 
6-mercaptopurine in nontransplant models. With the 
demonstration by Schwartz and Dameshek and 
workers in other laboratories that the drug mitigated 
the rejection of skin and kidney allografts in rats and 
dogs, respectively, the stage was set for the introduc-
tion by Murray et al. of the 6-mercaptopurine analogue 
azathioprine for clinical renal transplantation. 18 The 
combination of this drug with prednisone19 permitted 
a treatment policy to be evolved that could be used 
with a succession of baseline drugs-azathioprine, cy-
clophosphamide, cyclosporine, and FK 506-over the 
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next 30 years. In these drug cocktails, the dose-maneu-
verable prednisone allowed quick changes in immune 
modulation on a day-to-day basis. In 1966, antilym-
phocyte globulin (ALG) was added as a short-term 
adjunct for induction treatment or as a prednisone 
substitute for secondary intervention20; eventually 
these polyclonal preparations were succeeded by mono-
clonal ALGs such as OKT3. 
In late 1961, the Northwestern University experi-
mental transplant laboratory was moved to the Univer-
sity of Colorado, and a clinical kidney transplantation 
program was started there. After azathioprine-predni-
sone was shown to be effective antirejection therapy in 
a handful of kidney transplant recipients in 1962 and 
1963, a decision was made to move on to the liver. 21 
The first attempt at liver replacement on March 1, 
1963, ended tragically when a child with biliary atresia 
and an intractable coagulopathy bled to death in the 
operating room of Colorado General Hospital. 
Through the rest of 1963 and January 1964, six more 
attempts were made-four in Denver and one each in 
Boston and Paris. When all of the patients died after 
6Y2-23 days, pessimism settled in worldwide with a 
self-imposed moratorium that lasted 3 years. The prin-
cipal concerns were that the methods of preservation 
did not allow time for the deliberate performance of 
such a complex operation, that the intraoperative med-
ical management (including coagulation) was not well 
enough understood to be manageable, and that the 
available immunosuppression was inadequate to con-
trol rejection. 
By the summer of 1967, these deficiencies had been 
at least partially rectified during an intensive period of 
laboratory research, and on July 23 the trial was re-
sumed with a 1 Y2-year-old girl whose liver contained a 
nonresectable hepatoma. Although she became the 
first long survivor after liver transplantation,22 it was 
not a time of triumph. The child died of recurrent 
cancer after 400 days, and for the next dozen years the 
I-year mortality rate never fell below 50% in cases that 
were accrued at the rate of about one per month. The 
terrible losses were concentrated in the first few post-
operative months. After this, the life survival curve 
flattened, leaving a residual group of stable and remark-
ably well survivors. Thirty (18%) of the first 170 pa-
tients in the consecutive series that started March 1, 
1963, and ended in December 1979 lived more than a 
decade, and 23 of these are still alive after 13-23 years. 
They were all treated with azathioprine (or cyclophos-
phamide), prednisone, and polyclonal ALG. 
The continuing survival of these patients was a 
mute testimonial for liver transplantation, but it was 
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asked increasingly if such a small dividend could jus-
tify the prodigious effort that had brought liver trans-
plantation this far. The same questions were being di-
rected to Roy Caine of Cambridge, England, who had 
opened a second liver program in February 1968. 
Other teams established subsequently in Hannover, 
Germany (Pichlmayr, 1972) and Paris (Bismuth, 
1974) also reported the nearly miraculous benefits of 
this operation when it was successful, but always with 
the notation that the mortality rate resulting from the 
operation was too great to allow its practical use. 
The frustration ended after CaIne's clinical intro-
duction of cyclosporine in 1979,23 when this drug was 
combined with prednisone or lymphoid depletion in 
the first of the cyclosporine-based cocktails. 24 Of our 
first 12 liver recipients treated with cyclosporine and 
prednisone, 11 lived for more than 1 year,25 and 7 are 
still alive more than a dozen years later. New programs 
proliferated worldwide as the news was confirmed that 
a I-year patient survival rate of at least 70% was readily 
achievable. With the substitution of FK 506 for cyclo-
sporine in 1989,26 the I-year patient and liver graft 
survival rate increased another 15% in the Pittsburgh 
experience, an improvement also recorded in a multi-
center European trial. By now, liver transplantation 
had become the accepted court of last appeal for al-
most all nonneoplastic liver diseases, and even for se-
lected patients with otherwise nonresectable hepatic 
malignancies. The principal limitation of the technol-
ogy quickly became an inadequate supply of organs to 
meet the burgeoning needs. 
Multivisceral and Intestinal 
Transplantation 
At the same time in the summer of 1958 as 
orthotopic liver transplantation was under develop-
ment in Boston and Chicago, Richard Lillehei of the 
University of Minnesota began studies of small intes-
tinal transplantation in dogs27 that led 8 years later to 
the first of numerous unsuccessful clinical trials. 28 Be-
tween 1967 and 1987, more than a dozen attempts 
failed during the operation or up to 76 days later, 
usually with the death of the patient. 29 :\lthough im-
provements in immunosuppression were being made 
that allowed long survival after intestinal transplanta-
tion in dogs and pigs, none of these human grafts 
throughout the two-decade span provided significant 
nutritional function. 
This barrier was broken in 1987 when graft func-
tion was recorded for more than a half year from a 
cadaveric intestine that was part of a multivisceral 
graft in a recipient treated with cyclosporinc, predni-
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sone, and OKT3. 3o The multivisceral operation had 
been developed in nonimmunosuppressed dogs in 
1959 during early research on liver transplantation. 31 
The allograft was envisioned as a grape cluster with a 
double central stem consisting of the celiac axis and 
superior mesenteric artery (Figure 2A). The grapes, or 
individual organs, could be removed or retained ac-
cording to the surgical objectives, but both arterial 
stem structures were preserved. The venous outflow 
was kept intact up to or beyond the liver. 
The first patient who survived the multi visceral 
operation under cyclosporine-based immunosuppres-
sion died after 192 days of a B-cell lymphoma, but 
other patients have been treated successfully with the 
full multi visceral operation using FK 506 and are alive 
after as long as 15 months (Table 1). A variant proce-
dure in which only the liver and small bowel are re-
tained (Figure 2B) was described by Grant et al. 32 This 
operation has been particularly useful in patients with 
the short gut syndrome who developed liver failure 
after prolonged hyperalimentationY Using FK 506, 
13 (76.5%) of 17 patients in the Pittsburgh series are 
alive after 4Y2-30 months - all but 1 liberated from 
total parenteral nutrition (TPN) (Table 1). 
The increasingly common use of such complex gas-
trointestinal grafts reactivated interest in an observa-
tion from the original multi visceral experiments in un-
modified dogs that rejection of the organs making up 
the composite graft was less severe than that found 
when the organs were transplanted individually.34 
This impression was confirmed and greatly extended 
in 1969 by CaIne et al.,35 who described in pig liver 
recipients the protection of kidney and skin grafts 
B 
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from the same donor, and by the Japanese surgeon 
Naoski Kamada, whose experiments were performed 
in rats. 
As recently as late 1991, some workers in the field 
believed that the protection to the intestine afforded 
by the concomitant transplantation of the liver from 
the same donor was sufficiently great to justify com-
bined liver and intestinal transplantation, even when 
only a technically simpler intestinal transplant was 
needed. Enthusiasm for this draconian strategy began 
to fade with the successful transplantation in March 
1989 of a cadaveric small intestine by Goulet et al. 36 of 
Paris and of an ileal segment from a living related 
donor by Deltz of Kiel, Germany. 
These were isolated straws in the wind. The routine 
survival of cadaveric intestinal recipients then became 
possible under immunosuppression with FK 506 in 
Pittsburgh (Table 1), where the results have been bet-
ter with isolated intestinal transplantation than with 
either the multi visceral operation or its liver-intestine 
variantY Eight of 9 recipients survive, of whom all 
but one are TPN free. The expected release of FK 506 
for general use in the near future is certain to stimulate 
rapid further development of the intestinal transplan-
tation field. 
When the intestine is transplanted alone, it is desir-
able and usually possible to drain its venous outflow 
into the host portal vein. However, the inability to do 
so for technical reasons and the consequent need to 
bypass the hepatotrophic contents of intestinal blood 
around the liver has not yet caused serious hepatic 
complications. 
Another variation of the multivisceral operation is 
Figure 2. The multivisceral 
transplantation originally devel-
oped in dogs (A) and (8) a com-
monly used variant in which the 
central organs (pancreas and 
duodenum) are removed. leav-
ing the liver and small bowel. 
These two procedures have 
been used successfully in hu-
mans and provided the first ex-
amples of functioning bowel al-
lografts. Inset: Anastomosis of 
host portal vein into graft portal 
vein. 
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Table 1. FK 506: Transplantation of Intestine Alone or As 
Part of Composite Graft 
TPN free 
Alive 
Dates n (1/29/93) Total Partial" 
Intestine 5/2/90 to 9 8 7 
6/7/92 
Liver-intestine 7/24/90 to 17 13 12 
9/7/92 
Multivisceral 10/14/91 to 3 3 2 
8/12/92 
"Night TPN only. 
bGraft removed after 239 days because of encephalitis and need to 
stop immunosuppression therapy. 
shown in the upper right portion of Figure 1, in which 
the stomach above and intestine below is discarded. 37 
The remaining pancreaticohepatic graft has been used 
as partial replacement for the organs removed at upper 
abdominal exenteration (spleen, liver, stomach, pan-
creas, duodenum, proximal jejunum, and ascending 
colon). In some of these so-called cluster recipients, 
the duodenum and a segment of the jejunum have been 
placed in continuity with the residual gastrointestinal 
tract from the outset. These short segmental bowel 
grafts along with the liver and pancreas have func-
tioned as long as 41/2 years. 
Graft Acceptance 
Throughout the modern history of transplanta-
tion, it has not been possible to comprehend, nor even 
to have a plausible theory about, how grafts were able 
with the aid of immunosuppression to weather the 
initial attack by the recipient immune system and later 
to merge half forgotten into the host. Study of the 
gastrointestinal organs and their recipients have pro-
vided unique insights into these processes. 38 In 1969, 
the liver became the first transplanted organ to be rec-
ognized as having a composite (chimeric) structure. It 
was noted that the Kupffer cells and other tissue leu-
kocytes became predominantly recipient phenotype 
within 100 days of transplantation, whereas the hepa-
tocytes permanently retained their donor specificity 
(Figure 3). At the time and long afterward, this trans-
formation was assumed to be unique to the hepatic 
allograft. 
However, 22 years later, first in rat models and then 
in humans, it was realized that the same process oc-
curred in all successfully transplanted intestines. The 
epithelium of the bowel remained that of the donor, 
whereas the lymphoid, dendritic, and other leukocytes 
of recipient origin quickly invaded and became the 
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dominant cells in the lamina propria, Peyer's patches, 
and mesenteric nodes. Subsequent studies of the kid-
ney and thoracic organs made it obvious that all 
whole-organ grafts underwent similar changes, differ-
ing only quantitatively in the number of substituted 
tissue leukocytes, which ranged from large in the case 
of the liver to small in such organs as the kidney and 
heart. 
What remained to be determined was the fate of the 
leukocytes vacating the grafts. The answers were pro-
vided by the longest survivors in the world after kid-
ney (30 years) or liver (23 years) transplantation, who 
came to Pittsburgh in the spring and early summer of 
1992 to be restudied. 38,39 Biopsy specimens were ob-
tained from each of these patients bearing someone 
else's liver or kidney, and also from more recently 
treated recipients of hearts, lungs, and intestines. The 
samples were taken from the transplanted organ as 
well as from the patient's own skin, lymph nodes, and 
other tissues. Then, after special staining procedures 
(immunostaining or sex identification after fluores-
cence in situ hybridization), the tissues were examined 
under the microscope to see if the individual cells that 
made them up had come from the organ donor, the 
recipient's own body, or both. Alternatively, the do-
nor and recipient contributions to any specimen could 
be separated by polymerase chain reaction ("DNA fin-
gerprinting") techniques. 
As the answers came from these analyses and from 
new laboratory experiments in animals, a grand design 
emerged (Figure 3) that was always the same no matter 
what the engrafted organ. Within minutes after restor-
ing the blood supply of any transplant, myriad sessile 
but potentially migratory leukocytes that are part of 
the normal structure of all organs left the graft and 
migrated all over the recipient, while similar recipient 
cells took their place in the transplant without disturb-
ing the highly specialized donor parenchymal cells. 
The relocated donor and recipient leukocytes learned 
to live in harmony, provided they were given suffi-
cient protection during their nesting, by immunosup-
pressive drugs. In this new context, the drugs could be 
viewed as traffic directors, allowing movement of the 
white cells in both directions (to and from the graft) 
but preventing the immune destruction that is the nor-
mal purpose of this traffic. 
It is not known yet how the two sets of white cells-
a small population of predominantly dendritic cells 
from the donated organ and a large one that is in es-
sence the entire recipient immune system of the pa-
tient-reach a "truce." This is so complete in some 
cases that immunosuppression can be stopped, particu-
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Mutual Natural 
Immunosuppressi on 
H V G (Rejection) 
larly after liver transplantation but less constantly with 
other organs. Such a stable biological state can be in-
duced more easily by the liver than by other trans-
planted organs because of the liver's higher content of 
the critical missionary leukocytes that apparently in-
clude pluripotent stem cells. This was thought to be 
the explanation for the protection afforded the intes-
tine by a concomitantly transplanted liver. 
While still incomplete, this much information al-
ready provides a tool with which to shape future strate-
gies. The migratory cells can be purified from the bone 
marrow or spleen of a donor and then infused to im-
prove the "acceptability" of various organs from that 
specific donor, including those taken from an animal 
for use in humans as xenografts. The cell-migration 
and mixed chimerism phenomena make comprehensi-
ble the unexpected inability of donor-recipient HLA 
matching to accurately predict the outcome of whole 
organ transplantation; neither the new organ nor its 
new host remains the same as at the time of the match-
ing tests_ 
Summary 
Over a period of 33 years, it has become possi-
ble to successfully transplant individual intra-abdomi-
nal viscera or combinations of these organs. The con-
sequences have been, first, new information about the 
metabolic interrelations that the visceral organs have 
in disease or health; second, the addition of several 
procedures to ~he treatment armamentarium of gastro-
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Figure 3. The phenomenon of 
cell migration (with repopula-
tion and chimerism), which is 
postulated to be the basis of 
graft acceptance. Note the in-
teraction at the site of donor-
recipient mutual cell engage-
ment. This is thought to be the 
first step toward donor-specific 
nonreactivity (tolerance) by a 
mechanism of peripheral clonal 
"silencing." 
intestinal diseases; and third, a more profound under-
standing of the means by which all whole organ grafts 
are accepted. 
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